Polymorphism in the Vesicular Monoamine Transporter 2 Gene Decreases the Risk of Parkinson's Disease in Han Chinese Men

Parkinson's Disease

Volumn 2015, Issue , 2015, Pages

  Yang, Xinglong ^a   Xu, Pingrong ^a   Zhao, Quanzhen ^a   An, Ran ^a   Jia, Hua ^a   Liu, Zhuolin ^b   Xu, Yanming ^a  

^a SICHUAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HAN CHINESE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84938125407     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2015/903164     Document Type: Article

References (54)

1. M. Asanuma, I. Miyazaki, and N. Ogawa, "Dopamine-or LDOPA-induced neurotoxicity: the role of dopamine quinoneformation and tyrosinase in a model of Parkinson's disease, "Neurotoxicity Research, vol. 5, no. 3, pp. 165-176, 2003.
2. D. G. Graham, "Oxidative pathways for catecholamines in thegenesis of neuromelanin and cytotoxic quinones, " MolecularPharmacology, vol. 14, no. 4, pp. 633-643, 1978.
3. E. V. Mosharov, K. E. Larsen, E. Kanter et al. , "Interplay betweencytosolic dopamine, calcium, and-synuclein causes selectivedeath ofsubstantia nigra neurons, " Neuron, vol. 62, no. 2, pp. 218-229, 2009.
4. M. K. Schafer, E. Weihe, and L. E. Eiden, "Localization andexpression of VMAT2 aross mammalian species: a translationalguide for its visualization and targeting in health and disease, "in Advances in Pharmacology, vol. 68, chapter 15, pp. 319-334, 2013.
5. T. J. Montine, M. J. Picklo, V. Amarnath, W. O. Whetsell Jr. , and D. G. Graham, "Neurotoxicity of endogenous cysteinylcatechols, "Experimental Neurology, vol. 148, no. 1, pp. 26-33, 1997.
6. T. G. Hastings, D. A. Lewis, and M. J. Zigmond, "Role ofoxidation in the neurotoxic effects of intrastriatal dopamineinjections, " Proceedings of the National Academy of Sciences ofthe United States of America, vol. 93, no. 5, pp. 1956-1961, 1996.
7. S. B. Berman and T. G. Hastings, "Dopamine oxidation altersmitochondrial respiration and induces permeability transitionin brain mitochondria: implications for Parkinson's disease, "Journal of Neurochemistry, vol. 73, no. 3, pp. 1127-1137, 1999.
8. M. E. Gluck, J. Ehrhart, E. Jayatilleke, and G. D. Zeevalk, "Inhibition of brain mitochondrial respiration by dopamine:involvement ofH2O2 and hydroxyl radicals but not glutathioneprotein-mixed disulfides, " Journal of Neurochemistry, vol. 82, no. 1, pp. 66-74, 2002.
9. K. S. Zafar, D. Siegel, and D. Ross, "Apotential role for cyclizedquinones derived from dopamine, DOPA, and 3, 4-dihydroxyphenylaceticacid in proteasomal inhibition, " Molecular Pharmacology, vol. 70, no. 3, pp. 1079-1086, 2006.
10. S.-K. Han and G. Cohen, "Inhibition of catalase in mesencephaliccultures by L-DOPA and dopamine, " NeurochemistryInternational, vol. 29, no. 6, pp. 645-649, 1996.
11. J. H. Kang and K. S. Kim, "Enhanced oligomerization of the-synuclein mutant by the Cu, Zn-superoxide dismutase andhydrogen peroxide system, " Molecules and Cells, vol. 15, no. 1, pp. 87-93, 2003.
12. B. Dehay, M. Bourdenx, P. Gorry et al. , "Targeting-synucleinfor treatment of Parkinson's disease:mechanistic and therapeuticconsiderations, " The Lancet Neurology, 2015.
13. A. Ulusoy, T. Bjrklund, K. Buck, and D. Kirik, "Dysregulateddopamine storage increases the vulnerability to-synuclein innigral neurons, " Neurobiology of Disease, vol. 47, no. 3, pp. 367-377, 2012.
14. G. Eisenhofer, I. J. Kopin, and D. S. Goldstein, "Catecholaminemetabolism: a contemporary view with implications for physiologyand medicine, " Pharmacological Reviews, vol. 56, no. 3, pp. 331-349, 2004.
15. L. Brighina, C. Riva, F. Bertola et al. , "Analysis of vesicularmonoamine transporter 2 polymorphisms in Parkinson's disease, "Neurobiology of Aging, vol. 34, no. 6, pp. 1712. e9-1712. e13, 2013.
16. S. Kariya, M. Hirano, N. Takahashi, Y. Furiya, and S. Ueno, "Lack of association between polymorphic microsatellites of theVMAT2 gene and Parkinson's disease in Japan, " Journal of theNeurological Sciences, vol. 232, no. 1-2, pp. 91-94, 2005.
17. I. Mizuta, W. Satake, Y. Nakabayashi et al. , "Multiple candidategene analysis identifies-synuclein as a susceptibility gene forsporadic Parkinson's disease, " Human Molecular Genetics, vol. 15, no. 7, pp. 1151-1158, 2006.
18. J. Simn-Snchez, C. Schulte, J. M. Bras et al. , "Genome-wideassociation study reveals genetic risk underlying Parkinson'sdisease, " Nature Genetics, vol. 41, no. 12, pp. 1308-1312, 2009.
19. N. Pankratz, J. B. Wilk, J. C. Latourelle et al. , "Genomewide associationstudy for susceptibility genes contributing to familialParkinson disease, " Human Genetics, vol. 124, no. 6, pp. 593-605, 2009.
20. H.-C. Fung, S. Scholz, M. Matarin et al. , "Genome-wide genotypingin Parkinson's disease and neurologically normal controls:first stage analysis and public release of data, " The LancetNeurology, vol. 5, no. 11, pp. 911-916, 2006.
21. D. M. Maraganore, M. de Andrade, T. C. Lesnick et al. , "Highresolutionwhole-genome association study of Parkinson disease, "American Journal of Human Genetics, vol. 77, no. 5, pp. 685-693, 2005.
22. H. Morino, T. Kawarai, Y. Izumi et al. , "A single nucleotidepolymorphism of dopamine transporter gene is associated withParkinson's disease, " Annals of Neurology, vol. 47, no. 4, pp. 528-531, 2000.
23. M. Nishimura, R. Kaji, M. Ohta, I. Mizuta, and S. Kuno, "Associationbetween dopamine transporter gene polymorphismand susceptibility to Parkinson's disease in Japan, " MovementDisorders, vol. 17, no. 4, pp. 831-832, 2002.
24. B. R. Ritz, A. D. Manthripragada, S. Costello et al. , "Dopaminetransporter genetic variants and pesticides in Parkinson's disease, "Environmental Health Perspectives, vol. 117, no. 6, pp. 964-969, 2009.
25. D. B. Calne, B. J. Snow, and C. Lee, "Criteria for diagnosingParkinson's disease, " Annals of Neurology, vol. 32, pp. S125-S127, 1992.
26. G. Thomas, R. Sinville, S. Sutton et al. , "Capillary and microelectrophoreticseparations of ligase detection reaction productsproduced from low-abundant point mutations in genomicDNA, " Electrophoresis, vol. 25, no. 10-11, pp. 1668-1677, 2004.
27. J. Marchini, B. Howie, S. Myers, G. McVean, and P. Donnelly, "Anewmultipointmethod for genome-wide association studiesby imputation of genotypes, " Nature Genetics, vol. 39, no. 7, pp. 906-913, 2007.
28. J. Marchini, Homepage of IMPUTE2, https://mathgen. stats. ox. ac. uk/impute/impute v2. html.
29. F. S. Hall, K. Itokawa, A. Schmitt et al. , "Decreased vesicularmonoamine transporter 2 (VMAT2) and dopamine transporter(DAT) function in knockout mice affects aging of dopaminergicsystems, " Neuropharmacology, vol. 76, pp. 146-155, 2014.
30. J. Tong, I. Boileau, Y. Furukawa et al. , "Distribution of vesicularmonoamine transporter 2 protein in human brain: implicationsfor brain imaging studies, " Journal of Cerebral Blood Flow &Metabolism, vol. 31, no. 10, pp. 2065-2075, 2011.
31. K.-J. Lin, Y.-H. Weng, C.-J. Hsieh et al. , "Brain imaging ofvesicular monoamine transporter type 2 in healthy agingsubjects by 18F-FP-(+)-DTBZ PET, " PLoS ONE, vol. 8, no. 9, Article ID e75952, 2013.
32. J. Lotharius and P. Brundin, "Impaired dopamine storageresulting from-synuclein mutations may contribute to thepathogenesis of Parkinson's disease, " Human Molecular Genetics, vol. 11, no. 20, pp. 2395-2407, 2002.
33. E. V. Mosharov, R. G. W. Staal, J. Bov et al. , "-synuclein overexpressionincreases cytosolic catecholamine concentration, "Journal of Neuroscience, vol. 26, no. 36, pp. 9304-9311, 2006.
34. L. Chen, Y. Ding, B. Cagniard et al. , "Unregulated cytosolicdopamine causes neurodegeneration associated with oxidativestress in mice, " The Journal of Neuroscience, vol. 28, no. 2, pp. 425-433, 2008.
35. G. W. Miller, T. N. Taylor, andW. M. Caudle, "VMAT2-deficientmice display nigral and extranigral pathology and motorand nonmotor symptoms of Parkinson's disease, " Parkinson'sDisease, vol. 2011, Article ID 124165, 9 pages, 2011.
36. F. C. Colpaert, "Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat, " Neuropharmacology, vol. 26, no. 9, pp. 1431-1440, 1987.
37. R. H. Silva, V. C. Abio, D. Torres-Leite et al. , "Concomitantdevelopment of oral dyskinesia and memory deficits inreserpine-treated male and female mice, " Behavioural BrainResearch, vol. 132, no. 2, pp. 171-177, 2002.
38. L. L. Skalisz, V. Beijamini, S. L. Joca, M. A. B. F. Vital, C. DaCunha, and R. Andreatini, "Evaluation of the face validity ofreserpine administration as an animal model of depression-Parkinson's disease association, " Progress in Neuro-Psychopharmacologyand Biological Psychiatry, vol. 26, no. 5, pp. 879-883, 2002.
39. A. Bilska, M. Dubiel, M. Sokoowska-Jezewicz, E. Lorenc-Koci, and L. Wodek, "Alpha-lipoic acid differently affects thereserpine-induced oxidative stress in the striatum and prefrontalcortex of rat brain, " Neuroscience, vol. 146, no. 4, pp. 1758-1771, 2007.
40. V. S. Fernandes, J. R. Santos, A. H. Leaõ et al. , "Repeatedtreatment with a low dose of reserpine as a progressive model ofParkinson's disease, " Behavioural Brain Research, vol. 231, no. 1, pp. 154-163, 2012.
41. W.-S. Choi, H.-W. Kim, and Z. Xia, "JNK inhibition of VMAT2contributes to rotenone-induced oxidative stress and dopamineneuron death, " Toxicology, vol. 328, pp. 75-81, 2015.
42. S. J. Podurgiel, E. J. Nunes, S. E. Yohn et al. , "The vesicularmonoamine transporter (VMAT-2) inhibitor tetrabenazineinduces tremulous jaw movements in rodents: implications forpharmacologicalmodels of parkinsonian tremor, " Neuroscience, vol. 250, pp. 507-519, 2013.
43. H. J. Choi, S. Y. Lee, Y. Cho, and O. Hwang, "Inhibition ofvesicular monoamine transporter enhances vulnerability ofdopaminergic cells: relevance to Parkinson's disease, " NeurochemistryInternational, vol. 46, no. 4, pp. 329-335, 2005.
44. J. G. Truong, K. S. Rau, G. R. Hanson, and A. E. Fleckenstein, "Pramipexole increases vesicular dopamine uptake: implicationsfor treatment of Parkinson's neurodegeneration, " EuropeanJournal of Pharmacology, vol. 474, no. 2-3, pp. 223-226, 2003.
45. J. G. Truong, G. R. Hanson, and A. E. Fleckenstein, "Apomorphineincreases vesicular monoamine transporter-2 function:implications for neurodegeneration, " European Journal of Pharmacology, vol. 492, no. 2-3, pp. 143-147, 2004.
46. Z. Lin, D. Walther, X.-Y. Yu, S. Li, T. Drgon, and G. R. Uhl, "SLC18A2 promoter haplotypes and identification of a novelprotective factor against alcoholism, " Human Molecular Genetics, vol. 14, no. 10, pp. 1393-1404, 2005.
47. G. F. Wooten, L. J. Currie, V. E. Bovbjerg, J. K. Lee, and J. Patrie, "Are men at greater risk for Parkinson's disease than women"Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 4, pp. 637-639, 2004.
48. S. Petrovska, B. Dejanova, and V. Jurisic, "Estrogens: mechanismsof neuroprotective effects, " Journal of Physiology andBiochemistry, vol. 68, no. 3, pp. 455-460, 2012.
49. S. Al Sweidi, M. G. Snchez, M. Bourque, M. Morissette, D. Dluzen, and T. di Paolo, "Oestrogen receptors and signallingpathways: implications for neuroprotective effects of sexsteroids in Parkinson's disease, " Journal of Neuroendocrinology, vol. 24, no. 1, pp. 48-61, 2012.
50. K. A. Disshon andD. E. Dluzen, "Use of in vitro superfusion toassess the dynamics of striatal dopamine clearance: influence ofestrogen, " Brain Research, vol. 842, no. 2, pp. 399-407, 1999.
51. K. A. Disshon, J. W. Boja, and D. E. Dluzen, "Inhibition of striataldopamine transporter activity by 17-estradiol, " EuropeanJournal of Pharmacology, vol. 345, no. 2, pp. 207-211, 1998.
52. S. Jourdain, M. Morissette, N. Morin, and T. Di Paolo, "Oestrogensprevent loss of dopamine transporter (DAT) and vesicularmonoamine transporter (VMAT2) in substantianigra of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mice, " Journal ofNeuroendocrinology, vol. 17, no. 8, pp. 509-517, 2005.
53. K. M. Smith and N. Dahodwala, "Sex differences in Parkinson'sdisease and other movement disorders, " Experimental Neurology, vol. 259, pp. 44-56, 2014.
54. A. F. Wright, A. D. Carothers, and M. Pirastu, "Populationchoice in mapping genes for complex diseases, " Nature Genetics, vol. 23, no. 4, pp. 397-404, 1999.